Crestwood Advisors Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.32M Sell
137,811
-7,511
-5% -$196K 0.05% 191
2026
Q1
$4.08M Buy
145,322
+5,394
+4% +$144K 0.07% 159
2025
Q4
$3.48M Sell
139,928
-3,420
-2% -$86.2K 0.06% 169
2025
Q3
$3.65M Buy
143,348
+348
+0.2% +$8.59K 0.06% 159
2025
Q2
$3.47M Buy
143,000
+6,851
+5% +$160K 0.06% 161
2025
Q1
$3.45M Sell
136,149
-1,748
-1% -$45.7K 0.07% 153
2024
Q4
$3.66M Buy
137,897
+3,382
+3% +$91.7K 0.07% 143
2024
Q3
$3.89M Buy
134,515
+311
+0.2% +$9.07K 0.07% 141
2024
Q2
$3.76M Sell
134,204
-10,194
-7% -$281K 0.08% 136
2024
Q1
$4.01M Sell
144,398
-3,973
-3% -$110K 0.09% 133
2023
Q4
$4.27M Sell
148,371
-4,699
-3% -$142K 0.1% 129
2023
Q3
$5.08M Buy
153,070
+122,636
+403% +$4.34M 0.13% 113
2023
Q2
$1.12M Buy
30,434
+1,037
+4% +$40.4K 0.04% 135
2023
Q1
$1.2M Sell
29,397
-1,463
-5% -$63.2K 0.04% 133
2022
Q4
$1.58M Sell
30,860
-1,138
-4% -$54.6K 0.05% 120
2022
Q3
$1.4M Buy
31,998
+228
+0.7% +$11.1K 0.05% 125
2022
Q2
$1.67M Sell
31,770
-1,923
-6% -$98K 0.06% 124
2022
Q1
$1.74M Buy
33,693
+1,384
+4% +$71.8K 0.05% 127
2021
Q4
$1.91M Buy
32,309
+122
+0.4% +$6.04K 0.05% 126
2021
Q3
$1.38M Buy
32,187
+1,534
+5% +$68K 0.04% 137
2021
Q2
$1.2M Sell
30,653
-3,933
-11% -$153K 0.03% 145
2021
Q1
$1.25M Buy
34,586
+2,100
+6% +$74.6K 0.04% 137
2020
Q4
$1.2M Buy
32,486
+3,789
+13% +$139K 0.04% 137
2020
Q3
$999K Sell
28,697
-528
-2% -$18.5K 0.04% 124
2020
Q2
$907K Sell
29,225
-1,715
-6% -$58.3K 0.04% 126
2020
Q1
$958K Sell
30,940
-2,811
-8% -$95.8K 0.05% 114
2019
Q4
$1.25M Sell
33,751
-27
-0.1% -$962 0.05% 124
2019
Q3
$1.15M Buy
33,778
+1,690
+5% +$61.5K 0.05% 122
2019
Q2
$1.32M Buy
32,088
+7,399
+30% +$294K 0.06% 120
2019
Q1
$995K Sell
24,689
-859
-3% -$34.4K 0.07% 83
2018
Q4
$1.06M Buy
25,548
+5,105
+25% +$212K 0.08% 76
2018
Q3
$855K Buy
20,443
+833
+4% +$32.1K 0.06% 80
2018
Q2
$759K Sell
19,610
-707
-3% -$24.2K 0.06% 83
2018
Q1
$684K Sell
20,317
-2,539
-11% -$87.3K 0.05% 87
2017
Q4
$785K Buy
22,856
+1,937
+9% +$66K 0.06% 85
2017
Q3
$709K Buy
20,919
+174
+0.8% +$5.59K 0.06% 88
2017
Q2
$652K Buy
20,745
+6,008
+41% +$189K 0.06% 90
2017
Q1
$470K Sell
14,737
-4,398
-23% -$139K 0.04% 99
2016
Q4
$590K Buy
19,135
+1,122
+6% +$34.3K 0.06% 91
2016
Q3
$579K Sell
18,013
-316
-2% -$10.6K 0.07% 73
2016
Q2
$612K Sell
18,329
-105
-0.6% -$3.35K 0.08% 72
2016
Q1
$518K Sell
18,434
-43
-0.2% -$1.23K 0.06% 87
2015
Q4
$566K Buy
18,477
+707
+4% +$22.2K 0.07% 90
2015
Q3
$530K Sell
17,770
-246
-1% -$7.89K 0.07% 84
2015
Q2
$573K Buy
18,016
+896
+5% +$29.2K 0.08% 81
2015
Q1
$565K Sell
17,120
-274
-2% -$8.71K 0.08% 76
2014
Q4
$514K Sell
17,394
-1,107
-6% -$31.7K 0.08% 74
2014
Q3
$519K Buy
18,501
+843
+5% +$23.7K 0.08% 71
2014
Q2
$497K Buy
17,658
+63
+0.4% +$1.8K 0.08% 71
2014
Q1
$536K Sell
17,595
-1,668
-9% -$49.7K 0.09% 68
2013
Q4
$560K Sell
19,263
-1,937
-9% -$56.4K 0.09% 68
2013
Q3
$578K Buy
21,200
+2,108
+11% +$57.4K 0.1% 67
2013
Q2
$507K Buy
+19,092
New +$528K 0.09% 71

Other funds holding PFE

Crestwood Advisors Group's PFE Position: Q2 2026 in Review

Crestwood Advisors Group reduced its Pfizer (PFE) stake by 5.2% in Q2 2026, selling an estimated $196K and leaving 137,811 shares worth $3.32M. The position accounts for 0.05% of the portfolio, ranked #191.

Crestwood Advisors Group first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $5.08M in Q3 2023. 2,824 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Crestwood Advisors Group held 137,811 shares of Pfizer worth $3.32M as of Q2 2026.
  • Crestwood Advisors Group sold 7,511 Pfizer shares in Q2 2026, an estimated $196K.
  • Pfizer made up 0.05% of Crestwood Advisors Group's portfolio in Q2 2026, its #191 holding.
  • Crestwood Advisors Group first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Crestwood Advisors Group's Pfizer position peaked at $5.08M in Q3 2023.
  • 2,824 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Crestwood Advisors Group's 13F filing for Q2 2026, filed 3 Aug 2026.